Difference between revisions of "B72.3"
Jump to navigation
Jump to search
(→Use) |
|||
| Line 18: | Line 18: | ||
==Use== | ==Use== | ||
===Negative=== | |||
*[[Mesothelioma]] - stains ~3% (6 of 196<ref name=pmid29048219/>). | |||
===Positive=== | ===Positive=== | ||
* | *Most carcinomas.<ref name=pmid1866206>{{Cite journal | last1 = Betta | first1 = PG. | last2 = Pavesi | first2 = M. | last3 = Pastormerlo | first3 = M. | last4 = Tallarida | first4 = F. | last5 = Bellingeri | first5 = D. | last6 = Bocca | first6 = R. | title = Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. | journal = Pathologica | volume = 83 | issue = 1083 | pages = 99-104 | month = | year = | doi = | PMID = 1866206 }}</ref> | ||
=== | |||
==See also== | ==See also== | ||
Revision as of 22:23, 22 January 2019
| B72.3 | |
|---|---|
| Immunostain in short | |
| Use | mesothelioma versus carcinoma |
| Normal staining pattern | cytoplasmic |
| Positive | malignant mesothelioma |
| Negative | most carcinomas |
B72.3 in an immunostain useful in the diagnosis of malignant mesothelioma.[1]
Use
Negative
- Mesothelioma - stains ~3% (6 of 196[1]).
Positive
- Most carcinomas.[2]
See also
References
- ↑ 1.0 1.1 Tandon, RT.; Jimenez-Cortez, Y.; Taub, R.; Borczuk, AC. (Feb 2018). "Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.". Arch Pathol Lab Med 142 (2): 236-242. doi:10.5858/arpa.2017-0092-OA. PMID 29048219.
- ↑ Betta, PG.; Pavesi, M.; Pastormerlo, M.; Tallarida, F.; Bellingeri, D.; Bocca, R.. "Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.". Pathologica 83 (1083): 99-104. PMID 1866206.